APA (7th ed.) Citation

LI, Z., WEI, T., ZENG, D., ZHAO, L., ZHANG, J., & CHEN, L. (2024). First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient 
with EGFR Exon 20 Insertion Mutantion. Chinese Anti-Cancer Association; Chinese Antituberculosis Association.

Chicago Style (17th ed.) Citation

LI, Zhengguo, Ting WEI, Duo ZENG, Li ZHAO, Jianting ZHANG, and Laixiu CHEN. First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient 
with EGFR Exon 20 Insertion Mutantion. Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2024.

MLA (9th ed.) Citation

LI, Zhengguo, et al. First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient 
with EGFR Exon 20 Insertion Mutantion. Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2024.